222 related articles for article (PubMed ID: 27620209)
1. In-vitro influence of mycophenolate mofetil (MMF) and Ciclosporin A (CsA) on cytokine induced killer (CIK) cell immunotherapy.
Bremm M; Huenecke S; Zimmermann O; Pfirrmann V; Quaiser A; Bonig H; Soerensen J; Klingebiel T; Rettinger E; Bader P; Cappel C
J Transl Med; 2016 Sep; 14(1):264. PubMed ID: 27620209
[TBL] [Abstract][Full Text] [Related]
2. Mycophenolic acid inhibits natural killer cell proliferation and cytotoxic function: a possible disadvantage of including mycophenolate mofetil in the graft-versus-host disease prophylaxis regimen.
Ohata K; Espinoza JL; Lu X; Kondo Y; Nakao S
Biol Blood Marrow Transplant; 2011 Feb; 17(2):205-13. PubMed ID: 20736080
[TBL] [Abstract][Full Text] [Related]
3. Human interferon-alpha increases the cytotoxic effect of CD56(+) cord blood-derived cytokine-induced killer cells on human B-acute lymphoblastic leukemia cell lines.
Durrieu L; Gregoire-Gauthier J; Dieng MM; Fontaine F; le Deist F; Haddad E
Cytotherapy; 2012 Nov; 14(10):1245-57. PubMed ID: 22974386
[TBL] [Abstract][Full Text] [Related]
4. [Thymoglobulin efficiently expands cytokine-induced killer cells in a clinical-grade culture protocol].
Chen W; Lin D; Jiang Z; Yang Z; Song S; Zhou J; Zhou L; Sun Y; Yu H; Ma D
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jul; 30(7):681-5, 690. PubMed ID: 25001928
[TBL] [Abstract][Full Text] [Related]
5. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of mycophenolate mofetil and cyclosporine A on peripheral blood and cord blood natural killer cells activated with interleukin-2.
Derniame S; Perazzo J; Lee F; Domogala A; Escobedo-Cousin M; Alnabhan R; Luevano M; Pedroza-Pacheco I; Cooper N; Madrigal A; Saudemont A
Cytotherapy; 2014 Oct; 16(10):1409-18. PubMed ID: 24969967
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic potential of IL-15-activated cytokine-induced killer cells against human neuroblastoma cells.
Cappel C; Huenecke S; Suemmerer A; Erben S; Rettinger E; Pfirrmann V; Heinze A; Zimmermann O; Klingebiel T; Ullrich E; Bader P; Bremm M
Pediatr Blood Cancer; 2016 Dec; 63(12):2230-2239. PubMed ID: 27433920
[TBL] [Abstract][Full Text] [Related]
8. Improving Clinical Manufacturing of IL-15 Activated Cytokine-Induced Killer (CIK) Cells.
Bremm M; Pfeffermann LM; Cappel C; Katzki V; Erben S; Betz S; Quaiser A; Merker M; Bonig H; Schmidt M; Klingebiel T; Bader P; Huenecke S; Rettinger E
Front Immunol; 2019; 10():1218. PubMed ID: 31214182
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus-specific cytokine-induced killer cells: concurrent targeting of leukemia and cytomegalovirus.
Pfirrmann V; Oelsner S; Rettinger E; Huenecke S; Bonig H; Merker M; Wels WS; Cinatl J; Schubert R; Klingebiel T; Bader P
Cytotherapy; 2015 Aug; 17(8):1139-51. PubMed ID: 26072027
[TBL] [Abstract][Full Text] [Related]
10. Natural Killer Cell Activating Receptor NKG2D Is Involved in the Immunosuppressive Effects of Mycophenolate Mofetil and Hepatitis B Virus Infection.
Dong S; Geng L; Shen MD; Zheng SS
Am J Med Sci; 2015 May; 349(5):432-7. PubMed ID: 25828197
[TBL] [Abstract][Full Text] [Related]
11. Immunomagnetic selection or irradiation eliminates alloreactive cells but also reduces anti-tumor potential of cytokine-induced killer cells: implications for unmanipulated cytokine-induced killer cell infusion.
Rettinger E; Kreyenberg H; Merker M; Kuçi S; Willasch A; Bug G; Ullrich E; Wels WS; Bonig H; Klingebiel T; Bader P
Cytotherapy; 2014 Jun; 16(6):835-44. PubMed ID: 24582456
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-2-stimulated natural killer cells are less susceptible to mycophenolate mofetil than non-activated NK cells: possible consequences for immunotherapy.
Brehm C; Huenecke S; Esser R; Kloess S; Quaiser A; Betz S; Zimmermann O; Soerensen J; Passweg JR; Klingebiel T; Schwabe D; Bader P; Koehl U
Cancer Immunol Immunother; 2014 Aug; 63(8):821-33. PubMed ID: 24806448
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
[TBL] [Abstract][Full Text] [Related]
14. NKG2D Engagement Alone Is Sufficient to Activate Cytokine-Induced Killer Cells While 2B4 Only Provides Limited Coactivation.
Wu X; Sharma A; Oldenburg J; Weiher H; Essler M; Skowasch D; Schmidt-Wolf IGH
Front Immunol; 2021; 12():731767. PubMed ID: 34691037
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-6 inhibits regulatory T cells and improves the proliferation and cytotoxic activity of cytokine-induced killer cells.
Lin G; Wang J; Lao X; Wang J; Li L; Li S; Zhang J; Dong Y; Chang AE; Li Q; Li S
J Immunother; 2012 May; 35(4):337-43. PubMed ID: 22495391
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitors enhance cytotoxicity of cytokine-induced killer cells against human myeloid leukaemic blasts.
Poh SL; Linn YC
Cancer Immunol Immunother; 2016 May; 65(5):525-36. PubMed ID: 26961084
[TBL] [Abstract][Full Text] [Related]
17. Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes.
Franceschetti M; Pievani A; Borleri G; Vago L; Fleischhauer K; Golay J; Introna M
Exp Hematol; 2009 May; 37(5):616-628.e2. PubMed ID: 19375652
[TBL] [Abstract][Full Text] [Related]
18. Implication of different effector mechanisms by cord blood-derived and peripheral blood-derived cytokine-induced killer cells to kill precursor B acute lymphoblastic leukemia cell lines.
Durrieu L; Lemieux W; Dieng MM; Fontaine F; Duval M; Le Deist F; Haddad E
Cytotherapy; 2014 Jun; 16(6):845-56. PubMed ID: 24529554
[TBL] [Abstract][Full Text] [Related]
19. [Autologous CIK cell infusion promotes amplification ability of CD3⁺ CD56⁺ cells when re-preparation from patients with malignant tumors].
Yu H; Sun Y; Lin D; Li C; Chen W; Ma D
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jul; 30(7):748-53, 758. PubMed ID: 25001943
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic characterization and anticancer capacity of CD8+ cytokine-induced killer cells after antigen-induced expansion.
Liu J; Wang L; Wang Y; Zhang W; Cao Y
PLoS One; 2017; 12(4):e0175704. PubMed ID: 28426690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]